Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID [clinicaltrials:NCT00235053]

Bio2RDF identifier

NCT00235053

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00235053

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00235053

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:ca1954f55de6b13c270f49787460e895

brief summary [clinicaltrials_vocabulary:brief-summary]

This Pilot study is des ...... owed by a larger scale study.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Study to Assess the Incidence ...... f Advair DISKUS 250/50 Mcg BID

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

To determine the magnitude of change from baseline to end of study in the Voice Handicap Index (VHI) with Advair® DISKUS 250/50 mcg BID in subjects with mild persistent asthma. [clinicaltrials_resource:c58f78a54757f6ce01e4ce0d2d86304c]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

To determine the magnitude of change from baseline to end of study in the Voice Handicap Index (VHI) with Advair® DISKUS 250/50 mcg BID in subjects with mild persistent asthma. [clinicaltrials_resource:1799ce928a42a7c76ff88e2b41b0a100]

To determine the magnitude of change from baseline to end of study in the Voice Handicap Index (VHI) with Advair® DISKUS 250/50 mcg BID in subjects with mild persistent asthma. [clinicaltrials_resource:231d90c4f0f5621abf932e94b6017ff8]

To determine the magnitude of change from baseline to end of study in the Voice Handicap Index (VHI) with Advair® DISKUS 250/50 mcg BID in subjects with mild persistent asthma. [clinicaltrials_resource:2532d53d7f08b9534ef3b5429ac0e2ee]

To determine the magnitude of change from baseline to end of study in the Voice Handicap Index (VHI) with Advair® DISKUS 250/50 mcg BID in subjects with mild persistent asthma. [clinicaltrials_resource:2aa7d757c1ed647c326aed4794f20bcb]

To determine the magnitude of change from baseline to end of study in the Voice Handicap Index (VHI) with Advair® DISKUS 250/50 mcg BID in subjects with mild persistent asthma. [clinicaltrials_resource:72d081f3ba372c67fb68fad68f4be0eb]

To determine the magnitude of change from baseline to end of study in the Voice Handicap Index (VHI) with Advair® DISKUS 250/50 mcg BID in subjects with mild persistent asthma. [clinicaltrials_resource:8c64959c86de8ddec0419cf1a7c62399]

To determine the magnitude of change from baseline to end of study in the Voice Handicap Index (VHI) with Advair® DISKUS 250/50 mcg BID in subjects with mild persistent asthma. [clinicaltrials_resource:b7873b6eec47818c650a6812192572fd]

To determine the magnitude of change from baseline to end of study in the Voice Handicap Index (VHI) with Advair® DISKUS 250/50 mcg BID in subjects with mild persistent asthma. [clinicaltrials_resource:c81aeee69f6529ee1b269b924189292a]

To determine the magnitude of change from baseline to end of study in the Voice Handicap Index (VHI) with Advair® DISKUS 250/50 mcg BID in subjects with mild persistent asthma. [clinicaltrials_resource:e79504cacd83eb4652ad40871d3ee39b]

To determine the magnitude of change from baseline to end of study in the Voice Handicap Index (VHI) with Advair® DISKUS 250/50 mcg BID in subjects with mild persistent asthma. [clinicaltrials_resource:f9d7aeab56a7dc555afb024e5419f795]

completion date [clinicaltrials_vocabulary:completion-date]

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

Asthma is a chronic inf ...... objectively that effect.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00235053 [clinicaltrials_resource:fb4c62067f9c5faf9c12191927fba8e1]

enrollment [clinicaltrials_vocabulary:enrollment]

13

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

fluticasone/salmeterol DISKUS 250/50 [clinicaltrials_resource:23518c201ed6d73b91e319954e87af9f]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Fluticasone, salmeterol drug combination [clinicaltrials_resource:031acb2a75fb3b0f447da153497f62db]

Albuterol [clinicaltrials_resource:88bd0717ac36d10ddf011a2eff2c4172]

keyword [clinicaltrials_vocabulary:keyword]

asthma

http://www.w3.org/2001/XMLSchema#string

candidiasis, oral

http://www.w3.org/2001/XMLSchema#string

voice disorders

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2006-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Allergy & Asthma Medical Group & Research Center [clinicaltrials_resource:d63621a2c11af440d1f62282670223c6]

location [clinicaltrials_vocabulary:location]

Allergy & Asthma Medical Group & Research Center [clinicaltrials_resource:3bce8b6aa7174aa4b6c6a1d2e2e5485d]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00235053

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A Pilot Study to Assess the In ...... ts With Mild Persistent Asthma

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

NONE0-L00081

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Eli O Meltzer, MD [clinicaltrials_resource:49aea0a022fecdd046729e0cb536a6f6]

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

United States: Institutional Review Board [clinicaltrials_resource:209dfa6d2dfa6030effb7fe0c6595e65]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

source [clinicaltrials_vocabulary:source]

Allergy & Asthma Medical Group & Research Center [clinicaltrials_resource:d63621a2c11af440d1f62282670223c6]

start date [clinicaltrials_vocabulary:start-date]

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00235053 study design [clinicaltrials_resource:3c68ba5041d46c395c38150640320504]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00235053

verification date [clinicaltrials_vocabulary:verification-date]

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00235053

http://www.w3.org/2001/XMLSchema#string

title

Study to Assess the Incidence ...... f Advair DISKUS 250/50 Mcg BID

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Study to Assess the Incidence ...... D [clinicaltrials:NCT00235053]

@en